SRx HEALTH SOLUTIONS, INC.
SRXHRESTATEMENT RISKFILING INTENSITYSRx HEALTH SOLUTIONS, INC. reads as Restatement Risk (composite 90/100); pressure / disclosure signals dominate the posture this cycle · primary market Healthcare.
Lens
Disclosed M&A capital (2023–2025)
$7M
vs $21M in 2020–2022
Disclosed transactions
N/A
1/3 active fiscal years in window
Buyer archetype
Selective Buyer
Acquisition use is visible but targeted.
Composite score
90
Restatement Risk dominates · Filing Intensity
Behavioral posture, nine reads.
Each index scores the issuer 0–100 against an EDGAR-anchored definition. Scores ≥ threshold elevate the issuer into the index's constituent set; the dominant index drives the masthead label.
Active Acquirer
Companies actively deploying disclosed capital into M&A
- $28M disclosed buyer spend
Buyer Cadence
Buyer-side companies with recent filing activity
- Filed within 49d
- 184 8-Ks
Target Probability
Issuers showing target-side patterns from filings
- Control-process language
- 5 activism filings
Spin/Carve
Issuers showing spin-off, carve-out, or sum-of-parts posture
- 5 activism filings
Pressure Watch
Issuers facing activism, governance, or control pressure
- 5 activism filings
- Latest activism 10y ago; heavily discounted
- Control-process filings
Distress Watch
Issuers showing financial-distress filing patterns
- 5 activism filings
Restatement Risk
DominantIssuers with accounting-integrity flags from filings
- 1 non-reliance 8-K
- 7 auditor changes
- 21 NT late filings
- Latest event 9mo ago
Capital Velocity
Issuers with the highest filing-activity intensity
- 184 8-Ks
- 5 form types
Quiet Power
Large issuers with low signal volume and clean disclosure cadence
- Enterprise value $12M
- 10-Q 117d ago
- 4 active signals
Capital cadence.
Ten-year disclosed M&A activity. Bars show spend ($MM); ticks show recorded transaction count. Disclosure tier annotated where v6 audited corpus carries an entry.
Disclosed spend $MM Disclosed transactions (right axis)Peak spend year: $21M · Peak count: 1
| FY | Disclosed buys | Disclosed spend | Avg ticket | Audited tier |
|---|---|---|---|---|
| 2025 | N/A | $7M | N/A | N/A |
| 2024 | N/A | N/A | N/A | N/A |
| 2023 | N/A | N/A | N/A | N/A |
| 2022 | N/A | N/A | N/A | N/A |
| 2021 | N/A | N/A | N/A | N/A |
| 2020 | 1 | $21M | $21M | N/A |
Filing language.
Direct excerpts from acquisition disclosures and strategy sections: the verbs the buyer chose, in the filings they signed.
“These conditions raise substantial doubt about our ability to continue as a going concern for a period of twelve months from the date these interim condensed consolidated financial statements are issued, meaning that we may be unable to generate sufficient operating cash flows to pay our short-term obligations.”
“As a result of this competition, we may be unable to maintain our operations or develop them as currently proposed, on terms we consider acceptable, or at all.”
“We have historically incurred losses and expect to continue to generate operating losses and consume cash resources in the near term.”
“We expect to face additional competition from new market entrants that are selling and marketing new cannabis products and marijuana.”
Market context.
Where this issuer sits inside its SE-Cluster rollup wedge, with disclosed-spend rank plus trading comparables against the public peer set.
Primary market
Healthcare
- Market spend (2023–2025)
- $195B
- Market spend (2020–2022)
- $253.6B
- Recent vs prior
- −23%
- Issuer rank in market
- N/A
- Share of market capital
- 0.0%
Valuation positioning
SRXH trades at a -13.3-turn discount to the Healthcare peer median of 12.9×.
- EV / Revenue
- N/A
- Net debt / EBITDA
- N/A
- Peer median EV / EBITDA
- 12.9×
Trading comparables
FMP market data · 2026-05-10
| Company | EV / EBITDA | EV / Rev | Net debt / EBITDA | Revenue | M&A 2023–2025 |
|---|---|---|---|---|---|
AbbVie Inc.ABBV | 23.4× | 6.7× | 3.1× | $62.8B | $18B |
| 17.2× | 0.9× | 1.9× | $449.7B | $28.1B | |
Amgen Inc.AMGN | 12.9× | 6.0× | 2.6× | $37.2B | $26.7B |
| 11.7× | 0.5× | 2.5× | $200.4B | $6.4B | |
| 9.3× | 1.9× | 2.8× | $76.4B | $1.3B |
Trading multiples from FMP market data; disclosed M&A spend from the SE-Cluster EDGAR 10-K corpus. Peer set = top disclosed buyers in Healthcare. Bars scaled to the highest EV/EBITDA in the set.
Buyer landscape.
Public buyers whose stated archetypes, target categories, and recent cadence align with this issuer as a plausible acquisition target. Scores cross EDGAR signal and disclosure overlap.
Likely buyers
No public buyers surface as a strong target-side fit on current signal.
Likely sellers / divestiture partners
No reciprocal divestiture / strategic-alternatives matches identified.
Filing activity & signal stream.
Filing cadence and event-driven signals visible on EDGAR. The signal stream below is curated from restatement / spin-carve / activism categories, providing context for any near-term call.
Filing cadence
- 10-K (annual)182025-12-05
- 10-Q (quarterly)492026-02-13
- 8-K (event)1842026-04-22
- Proxy / DEF 14A92025-03-07
- Activism (13D / DFAN / PREC)52016-02-08
Signals on file
- critical
Non-reliance disclosure
2018-10-301 Item 4.02 filing on file; financial-statement non-reliance.
- elevated
Auditor change
2025-09-197 Item 4.01 filings on file; certifying accountant change.
- watch
Late-filing notice
2025-08-1421 NT 10-K/10-Q filings on file.
- elevated
Activism on file
2016-02-085 activist filings on file (13D, DFAN14A, PREC14A series).
- info
Signal
Serial acquisition history
- info
Signal
Recent transaction activity
- info
Signal
Control-process filings
Audited corpus.
No audited record on file for this CIK in the current v6 corpus.
This issuer has not been extracted into the v6 audited acquirer corpus yet. The brief above pulls from ranking-level aggregates and issuer-index signal only.